RSS Feeds




AdVac® Technology: Manufacturing Platform for Vaccines More
Hansenula polymorpha: An Expression System for the Synthesis of Pharmaceutical Compounds More
MAbstract® Technology for Antibody Discovery More
PER.C6® Technology: Vaccine and Protein Production More
Recombinant Paramyxovirus: Development of Novel Measles Vaccines More
Virosome Technology: Target-Specific Delivery of Antigens and Amplification of the Immune Response More


On November 2, 2005 - Dutch biotechnology company Crucell Nhas licensed bacterial antigens from ACE BioSciences A/S and the Brigham and Women's Hospital, a teaching hospital of Harvard Medical School, to accelerate its bacterial antibody discovery program.

On August 17, 2005 - Dutch biotechnology company Crucell signed a cooperative research and development agreement (CRADA) with the Naval Medical Research Center of the US Navy to construct AdVac®-based vaccines against anthrax and plague and test them in non-human primates.

On July 15, 2005 - Dutch biotechnology company Crucell Nand allied contract manufacturer DSM Biologics have signed a PER.C6® research license agreement with Danish biotechnology company Symphogen A/S.

On March 22, 2005 - Dutch biotechnology company Crucell signed a commercial PER.C6® license agreement with Singapore-based company SingVax Pte Ltd for the development and commercialisation of new vaccines against Japanese encephalitis.

In March 2004, Crucell and the Aeras Global TB Vaccine Foundation of Bethesda, Maryland, announced a new collaboration on the pre-clinical and clinical development of candidate tuberculosis (TB) vaccines. Aeras has agreed to provide Crucell up to USD$2.9 million contingent upon meeting certain development milestones, for development of TB vaccine candidates. Crucell and U.S.-based NeoTropiX also announced that they have entered into a PER.C6(TM) technology licensing agreement for viral therapy in the field of oncology.

In January 2004, Crucell signed a non-exclusive PER.C6(TM) technology research and commercialization license agreement with Biogen Idec for the production of recombinant proteins to be used in in-house antibody discovery programs. Aventis and Crucell also announced that they have entered into a strategic agreement to further develop and commercialize novel influenza vaccine products based on Crucell's proprietary PER.C6(TM) cell line technology. The agreement covers both pandemic and epidemic influenza vaccines, which up to now have been part of Crucell's in-house product development program.

Partners include Merck & Co. for the HIV vaccine, the National Institutes of Health (NIH) for the Ebola vaccine and Centocor, a Johnson & Johnson, for the CD46 antibody for treatment of various types of cancer. In addition, Crucell has over 20 licensees for its PER.C6(TM) technology including Novartis, GSK, Aventis and Schering.and Centocor, a Johnson & Johnson, for the CD46 antibody for treatment of various types of cancer. In addition, Crucell has over 20 licensees for its PER.C6(TM) technology including Novartis, GSK, Aventis and Schering.

Senior management

Ronald Brus, M.D. (President and Chief Executive Officer)
Dr. Brus has been a member of Crucell's Management Committee since the company's incorporation and was formerly COO (March 2003 to January 2004) and CBO (October 2000 to February 2003). Prior to that, Dr. Brus was EVP, Business Development at IntroGene after joining the company in 1997. From 1994 to 1996, he was Product Planning Physician at Forest Laboratories (New York) and from 1990 to 1994 he was Medical Director for Zambon. He holds a Medical degree from the University of Groningen.

Jaap Goudsmit,Ph.D. (Chief Scientific Officer)
Mr. Goudsmit is responsible for all R&D activities. Dr. Goudsmit joined Crucell in September 2001 as SVP, Vaccine Research. Prior to joining Crucell, Dr. Goudsmit held various positions at the Academic Medical Center at the University of Amsterdam. During his career, Dr. Goudsmit has been appointed Chairman to several national and international committees. Dr. Goudsmit has also taught and been a fellow at a number of institutions, such as the National Institutes of Health and New York University. Dr. Goudsmit is co-founder of both IAVI (International AIDS Vaccine Initiative) and EuroVac, the European Union AIDS vaccine effort. In July 2003, Dr. Goudsmit became Chairman of the Board of the AIDS Foundation East-West, a NGO focused on AIDS prevention in the countries of the former Soviet Union. He is a Board certified medical microbiologist and from 1989 to 2002 served as Professor of Virology at the University of Amsterdam. He received a Ph.D. in Virology as well as a Medical Degree from the University of Amsterdam. Dr. Goudsmit remains affiliated with the University of Amsterdam and the Amsterdam Medical Center as Professor of Poverty-related Communicable Diseases.

Leonard Kruimer, M.B.A., C.P.A. (Vice President and Chief Financial Officer)
Mr. Kruimer held the same position at IntroGene from 1998 to 2000. From 1996 to 1998 he was an independent Consultant with companies such as Pepsico and Royal Boskalis Westminster. From 1993 to 1995, Mr. Kruimer was the MD, continental Europe of GE Capital/TIP Europe. He has also held positions as MD of Kwik-Fit Europe B.V. and as Finance Director at Continental Can Europe. He was a Consultant at McKinsey & Company and has worked with Price Waterhouse. Mr. Kruimer holds a Masters in Business Administration from Harvard Graduate School of Business Administration, a degree from the University of Massachussets, Amherst, and is a C.P.A. in New York.

René Beukema (General Counsel and Corporate Secretary)
Mr. Beukema held the same position at IntroGene since 1999. From 1991 to 1994, Mr. Beukema was legal counsel for TNT Express Worldwide. From 1994 to 1999 he was Senior Legal Counsel for GE Capital/TIP Europe. He has a Masters in Law from the University of Amsterdam.

Arthur Lahr (Chief Strategy Officer and Executive Vice President and Business Development)
Mr. Lahr is Crucell's Chief Strategy Officer and Executive Vice President Sales & Business Development. He joined Crucell in April 2001 as Executive Director Business Development, was appointed Vice President Business Development in December 2003, a member of the Management Committee in January 2004, Executive Vice President in January 2006 and assumed responsibility for European marketing & sales and company strategy in the summer of 2006. From 1994 to 2001 he was a consultant with McKinsey & Co. in the Netherlands and New York. Prior to that he worked with Unilever. He holds a Masters in Business Administration from INSEAD and a Masters in Science, Applied Physics, from the University of Delft, the Netherlands.

Simon Rothen, Ph.D. (Chief Operations Officer)
Mr Rothen served as Chief Operations Officer of Berna Biotech from 2004 until its acquisition by Crucell. He joined Berna Biotech in 1998 where he fulfilled several positions in production, quality, IT/IS, supply chain and operations. Before joining Berna Biotech he worked for Novartis Pharma Biotechnology Development & Production (Technical Cell Biology). He studied biotechnology at ETH Zurich where he earned his Ph.D. in bioprocess engineering in 1997.

Björn Sjöstrand (Member of Crucell Management)
Mr. Sjöstrand is a member of Crucell's management committee charged with overseeing the company's vaccines business unit. He was the CEO at SBL Vaccines before it merged with Crucell in November 2006. Mr. Sjöstrand, a Swedish national, successfully headed the Crucell-SBL integration committee while directing the travel franchise and the Nordic sales force for the Crucell Group. He initiated and led a Management buyout of SBL Vaccin AB funded by 3i and SEB Företagsinvest. At SBL, he successfully implemented a triumphant, award-winning turnaround of the company from a loss-making company to a growth-focused, profit-making company between 2004 and 2006. Between 1999 and 2001, he was the Vice President Operations & IT at Active Biotech, where he was also a member of the Senior Management Team. Mr Sjöstrand completed a Bachelor of Science (BSc) degree in Economics and Business Administration at the University of Örebro. He also studied Financial Investment theory and Commercial law at the same university.

Kuno Sommer (Chief Business Officer)
Mr Sommer was Chief Executive Officer of Berna Biotech from 2000 until its acquisition by Crucell in 2006. He was CEO of Givaudan-Roure in Geneva and member of the executive committee of Roche AG in 1998/99. From 1995 he served as manager of Roche global marketing for the vitamin and speciality chemicals division in Basel, and from 1990 to 1994, he was head of the North American branch of the Roche animal feed and health division. Before 1990, Mr Sommer held various positions with Roche AG Vitamin Marketing. He studied economic science at Basel University and earned a doctorate in political science.

Board of directors

Jan Pieter Oosterveld, M.B.A. (Director)
Mr Oosterveld retired from Royal Philips Electronics on April 1, 2004, after an international career of 32 years. He was responsible for Corporate Strategy and Corporate Alliances while also filling the role of Asia Pacific CEO and Chairman of the Board of Directors of LG.Philips. He graduated as a Mechanical Engineer from the Technical University Eindhoven, holds an M.B.A. from the Instituto de Estudios Superiores de la Empresa (IESE) in Barcelona, and completed the Executive Program at the University of Michigan. He was appointed Professor at IESE in 2002.

Arnold Hovenaars (Director)
Mr. Hovenaars has been attending the Supervisory Board meetings as an observer since July 2004, and was officially appointed to the board at our AGM on June 2, 2005. Mr Hoevenaars is a chartered accountant in the Netherlands, and his previous positions include, among other, Chairman of the Management Board of the Achmea Group, Chairman of the Board of Directors and Chairman/CEO of the Executive Board of Eureko B.V. and member of the Management Board and Chief Financial Officer of Royal Boskalis Westminster N.V.

Dominik Koechlin (Director)
Mr. Koechlin has served as a member of our Supervisory Board since February 2006 upon settlement of Crucell's exchange offer for Berna Biotech AG, where he was a member of the Board of Directors. His career began in 1986 as a financial analyst at Bank Sarasin & Cie in Basel. In 1990 he was a founding partner of the consultancy firm Ellipson AG. In 1996 he became a member of the executive board of Telecom PTT, now known as Swisscom AG. In 1999 he took over responsibility for all of Swisscom's international participations. He has served on the boards of Debitel AG (Stuttgart), Bluewin AG, Swisscom USA and was chairman of the board of UTA (Vienna) and a member of the supervisory board of Cesky Telecom (Prague). He is currently a member of the supervisory boards and audit committees of LGT Bank (Liechtenstein), EGL AG and Swissmetal AG, and a board member at SAM, M2 and Corris AG.

Sean P. Lance (Director)
Mr. Lance has served as a member of Crucell's Supervisory Board since January, 2004. Mr Lance is Chairman of Chiron. He joined Chiron as President and CEO in 1998. From 1985 to 1998 he was with Glaxo Holdings where his last position was group COO and CEO designate. He is a past President of the International Federation of Pharmaceutical Manufacturers Association. He is currently Chairman of the Board of Directors for the Global Alliance for TB Drug Development, and is a member of the Board of Directors of the California Healthcare Institute. Mr. Lance is a chartered Company Secretary and Administrator and he also holds a post-graduate degree in Advanced Financial Management.

Philip M. Satow (Director)
Mr. Satow has been a member of Crucell's Supervisory Board since its incorporation. He spent 14 years at Pfizer (PFE-NYSE) where his last position was VP, Pharmaceutical Development, Pfizer Europe. From 1985 to 1997, he was EVP of marketing at Forest Laboratories. From 1998 to 1999, he was President of Forest Pharmaceuticals, EVP of Forest Laboratories and a member of its Board of Directors. Mr. Satow currently serves on the Boards of Forest Laboratories, The Columbia College Board of Visitors and the American Foundation of Suicide Prevention. Mr. Satow received a Masters in Economics from Georgetown University.

Claes E. Wilhelmsson, Ph.D. (Director)
Dr. Wilhelmsson has served as a member of Crucell's Supervisory Board since May 2003. He was Executive Director R&D of AstraZeneca from 1999 until July 2002, where he was responsible for AstraZeneca's global research and development. Dr Wilhelmsson joined Astra in 1985 and held various positions until the company merged with Zeneca in 1999. Prior to Astra, Dr. Wilhelmsson was a lecturer and researcher at the University of Göteborg in Sweden, where he also completed his medical education and Ph.D. He currently serves on the Boards of a number of biotechnology companies and is Chairman of the Board of Gyros. Dr. Wilhelmsson previously served on the Board of AstraZeneca.

Contact details

Arthur Lahr

Contact directly

Head office

Archimedesweg 4-6

Clients in focus...

Get the Flash Player to see this rotator.

© Copyright 1998-2014 IP Technology Exchange, Inc All rights reserved. Terms and Conditions | Contact us